Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Glioblastoma 1Colorectal Neoplasms 1Chromosome 17 deletion 1Breast Neoplasms 1

Interventions

Rituximab 48Cyclophosphamide 27Lenalidomide 23Peripheral Blood Stem Cell Transplantation 16obinutuzumab 10fludarabine phosphate 10Filgrastim 10Etoposide 10Bendamustine Hydrochloride 10Vincristine 8Prednisone 8Doxorubicin 8fludarabine 7Radiotherapy 7Mycophenolic Acid 7Melphalan 7Cyclosporine 7Bortezomib 7venetoclax 6tazemetostat 6ibritumomab tiuxetan 6Whole-Body Irradiation 6Gemcitabine 6pembrolizumab 5ibrutinib 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5CT-P10 5veltuzumab 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Follicular × RG7388 × Clear all
NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 1/2 Terminated
29 enrolled 18 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡